REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
4 hedge funds and large institutions have $749K invested in REGENERX BIOPHARMACEUTICALS in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
1,018% more capital invested
Capital invested by funds: $67K → $749K (+$682K)
20% less funds holding
Funds holding: 5 → 4 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PTC
Philadelphia Trust Company
Philadelphia,
Pennsylvania
|
-$60.9M |
| 2 |
FIM
Frontier Investment Management
Dallas,
Texas
|
-$16K |
RGN Hedge Fund Activity: Q1 2019 in Review
4 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q1 2019, worth a combined $749K — up 1,018% from $67K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RGN and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Philadelphia Trust Company, cutting an estimated $60.9M.
- 4 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q1 2019, down from 5 in Q4 2018.
- Funds reported $749K of REGENERX BIOPHARMACEUTICALS stock for Q1 2019, up 1,018% quarter-over-quarter.
- 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q1 2019 and 1 closed out, a net change of -1 holder.
- The largest REGENERX BIOPHARMACEUTICALS seller in Q1 2019 was Philadelphia Trust Company, an estimated $60.9M sold.
Based on aggregated 13F filings for Q1 2019.